Molecular Analysis for Precision Oncology Virtual Congress

Free Registration

MOLECULAR
ANALYSIS FOR
PRECISION
ONCOLOGY
VIRTUAL
CONGRESS

MAP

9-10 OCTOBER 2020

Chairs:
Fabrice André, Villejuif, France (Unicancer)
John Haanen, Amsterdam, Netherlands (ESMO)
Charles Swanton, London, UK (CRUK)

Organising partners:

CANCER
RESEARCH
UK

ESMO
GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

unicancer

map-onco.net

Welcome

MAP is a leading congress in precision medicine in oncology, established by key opinion leaders in the field. The name of the Congress was recently changed into Molecular Analysis for Precision Oncology to better reflect its aims of focusing on science, translational research, education and collaboration.

The MAP 2020 Virtual Congress will offer the same top-tier scientific research and education and industry engagement that congress attendees are accustomed to, in an all-new digital environment.

By attending MAP 2020, participants will learn how to integrate insights from tumour sample analysis into daily practice, how to seek and identify actionable mutations in patient DNA and how to provide the best possible personalised treatment.

Founded by Jean-Charles Soria, Fabrice André and Charles Swanton, the MAP Congress has established itself as a point of reference for all specialists wishing to create a bright future for precision medicine in oncology, by delivering a highly specific, minimally toxic and dramatically effective treatment for each patient.

The MAP Congress is the result of a close partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research.

We look forward to welcoming you online at the MAP 2020 Virtual Congress.

In the meantime, we hope you and your families stay safe and well.

Yours sincerely,
MAP 2020 Scientific Co-Chairs

**Fabrice André,
Villejuif, France**
Unicancer

**John Haanen,
Amsterdam,
Netherlands**
ESMO

**Charles Swanton,
London, UK**
CRUK

Congress Officers

SCIENTIFIC COMMITTEE CO-CHAIRS

Fabrice André, Villejuif, France (Unicancer)

John Haanen, Amsterdam, Netherlands (ESMO)

Charles Swanton, London, UK (CRUK)

SCIENTIFIC COMMITTEE

Geneviève Almouzni, Paris, France

Alberto Bardelli, Candiolo, Italy

Jean-Yves Blay, Lyon, France

Mariam Jamal-Hanjani, London, UK

Leeat Keren, Stanford, CA, USA

Sherene Loi, Melbourne, Australia

Sergio Quezada, London, UK

Wouter Scheper, Amsterdam, Netherlands

James Thaventhiran, Cambridge, UK

Daniela Thommen, Amsterdam, Netherlands

Clare Turnbull, London, UK

LEARNING OBJECTIVES

- ✓ Update your knowledge on molecular targets for the most frequent cancers

- ✓ Acquire a better understanding on tumour biology-related mechanisms as potential targets and resistance to therapy

- ✓ Follow-up on new data in Immuno-oncology (Mechanisms of toxicity, prognostic/predictive markers for therapy and monitoring)

- ✓ Learn about new targets and effectors (Gene Editing, CarT cells, Antibody-drug conjugates)

Programme

For the full and most updated overview, please visit __the online programme.__

12:00-12:10 **Opening and Welcome**
Welcome to MAP 2020, *Scientific Committee Co-Chairs*

12:10-13:20 **Session 1: Molecular targeting**
Chair: *F. André, Villejuif, France*

Metastatic lung cancer, *F. Barlesi, Villejuif, France*
Colon, *M. Chalabi, Amsterdam, Netherlands*
Bladder cancer, *F. Radvanyi, Paris, France*
Prostate, *J. S. de Bono, London, UK*
Live discussion

13:35-14:30 **Session 2: Epigenetics**
Chair: *G. Almouzni, Paris, France*

Chromatin remodelling, *J. Downs, London, UK*
Epigenetics and antitumor immunity, *G. Almouzni, Paris, France*
Epigenetics and intratumor heterogeneity, *R. Margueron, Paris, France*
Live discussion

14:45-15:40 **Session 3: Mechanisms of IO toxicity**
Chairs: *J. Thaventhiran, Cambridge, UK; J. Haanen, Amsterdam, Netherlands*

Genes regulating human immunity and care for patients with gene deficiencies in pathways targeted by checkpoint blockade, *J. Thaventhiran, Cambridge, UK*
Serum autoantibodies and irAEs, *J. Hassel, Heidelberg, Germany*
Interplay between steroids, immune targeting and GI toxicity, *T. Kirchhoff, New York, NY, USA*
Live discussion

15:55-17:05 **Session 4: Clonal evolution**
Chairs: *M. Jamal-Hanjani, London, UK; A. Bardelli, Candiolo, Italy*

Therapy-induced mutagenesis and drug resistance in colon cancer,
A. Bardelli, Candiolo, Italy
Tumour evolution from early to late stage disease in lung cancer,
M. Jamal-Hanjani, London, UK
The co-evolution of the genome and epigenome in colorectal
cancer, *A. Sottoriva, Sutton, UK*
Quantifying tumour evolution through treatment and metastasis,
C. Curtis, Stanford, CA, USA
Live discussion

17:20-18:00 **Mini Oral session**
Chair: *F. André, Villejuif, France*

1MO - A proteomics-based platform for predicting response to
immunotherapy and personalizing treatment plans, *Y. Shaked,
Haifa, Israel*

Live Q&A

2MO - Radiotherapy in cancer is associated with a deletion
signature that contributes to poor patient outcomes, *E. Kocakavuk,
Farmington, CT, USA*

Live Q&A

3MO - Mutational signatures in the perspective of tumour
mutational burden in patients with non-small-cell lung cancer,
G. Van den Heuvel, Hertogenbosch, Netherlands

Discussion, *K. Litchfield, London, UK*

4MO - MET exon 14 screening strategy, how not to miss large
deletions, *R. Loyaux, Paris, France*

Discussion, *A. Stenzinger, Heidelberg, Germany*

12:00-12:25   **Keynote address: Gordon Peters Lecture**
Chair: C. Swanton, London, UK
KRAS, *M. Barbacid Montalbán, Madrid, Spain*

12:40-13:50   **Session 5: Biomarkers for immunotherapeutics**
Chair: *S. Loi, Melbourne, Australia*

B cells and tertiary lymphoid structures as biomarkers for
immunotherapy, *W. Fridman, Paris, France*
Predictive value of the microbiome for immunotherapy,
L. Zitvogel, Villejuif, France
Multimodal genomic features to predict outcome of immune
checkpoint blockade, *E. Anagnostou, Baltimore, MD, USA*
Immune biomarkers and novel immunotherapeutics, *S. Loi,
Melbourne, Australia*
Live discussion

14:05-15:00   **Session 6: New technologies for therapeutic targeting**
Chair: *J. Haanen, Amsterdam, Netherlands*

Gene editing: CRISPR editing of T cells for TCR gene therapy,
D. Busch, Munich, Germany
To be announced, *A. Sewell, Cardiff, UK*
Antibody drug conjugates: For more mechanistic data on ADC
compounds and combination therapy, *D. Peeper, Amsterdam,
Netherlands*
Live discussion

15:15-16:25 **Session 7: Pancreatic cancers**
Chair: *A. Maitra, Houston, TX, USA*

Identifying high risk populations in pancreatic cancer using computational approaches, *N. Malats, Madrid, Spain*
Stromal heterogeneity in pancreatic cancer, *G. Biffi, Cambridge, UK*
Regulation of tumour biology by stromal components,
C. Jorgensen, Manchester, UK
Clinical implications of last advances in pancreatic cancers,
A. Maitra, Houston, TX, USA

Live discussion

16:40-17:35 **Session 8: In-situ tissue interpretation**
Chair: *L. Keren, Stanford, CA, USA*

Germline genetics, *C. Turnbull, London, UK*
Unravelling the tumour microenvironment by multiplexed imaging,
L. Keren, Stanford, CA, USA
Imaging immune cell dynamics and function,
C. Zhao, Bethesda, MD, USA
Live discussion